{"nctId":"NCT00242580","briefTitle":"A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib","startDateStruct":{"date":"2005-09"},"conditions":["Macular Degeneration","Choroidal Neovascularization"],"count":111,"armGroups":[{"label":"Verteporfin and Triamcinolone 1 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Verteporfin photodynamic therapy","Drug: Triamcinolone acetonide"]},{"label":"Verteporfin and Triamcinolone 4 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Verteporfin photodynamic therapy","Drug: Triamcinolone acetonide"]},{"label":"Verteporfin and Pegaptanib","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Verteporfin photodynamic therapy","Drug: Pegaptanib"]}],"interventions":[{"name":"Verteporfin photodynamic therapy","otherNames":["Visudyne"]},{"name":"Pegaptanib","otherNames":["Macugen"]},{"name":"Triamcinolone acetonide","otherNames":["Kenalog-40Â®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* age \\>50\n* all types of untreated subfoveal choroidal neovascularization secondary to AMD\n* lesion size \\<5400 microns in greater linear dimension (GLD)\n\nExclusion Criteria:\n\n* have a history of prior photodynamic therapy, external beam radiation, subfoveal focal laser photocoagulation, submacular surgery, or transpupillary thermotherapy\n* known allergy to verteporfin, triamcinolone or pegaptanib\n* have received prior treatment with Macugen, or other anti-angiogenic compound or any investigational treatment (e.g. Ruboxistaurin, Lucentis \\[ranibizumab\\], Retaane \\[anecortave acetate\\], squalamine, siRNA, VEGF-Trap etc.) for neovascular AMD\n* have the presence of fibrosis, hemorrhage, pigment epithelial detachments, tear (tip) of the retinal pigment epithelium or other hypoflourescent lesions obscuring greater than 50% of the CNV lesion\n* have had previous pars plana vitrectomy in the study eye\n\nOther protocol-specified inclusion/exclusion criteria applied.","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Lose Less Than 15 Letters of Best Corrected Visual Acuity (BCVA) at 12 Months From Baseline.","description":"BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. A decrease in score indicates worsening of vision. This outcome assessed the percentage of participants who lost less than 15 letters of visual acuity at 12 months as compared with baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.4","spread":null},{"groupId":"OG001","value":"63.4","spread":null},{"groupId":"OG002","value":"71.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Gain of 5 or More Letters of Best Corrected Visual Acuity From Baseline to Month 12","description":"BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained 5 or more letters of visual acuity at 12 months compared with baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"12.2","spread":null},{"groupId":"OG002","value":"28.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Gain of BCVA of 10 or More Letters at 12 Months","description":"BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained 10 or more letters of visual acuity at 12 months as compared with baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","spread":null},{"groupId":"OG001","value":"2.4","spread":null},{"groupId":"OG002","value":"23.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Gain of BCVA Score of 15 or More Letters at Month 12","description":"BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained 15 or more letters of visual acuity at 12 months as compared with baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"13.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Requiring Verteporfin Treatment Throughout the Study","description":"Participants received study drug at the Baseline visit and subsequent retreatment at 3 month intervals if leakage was detected on the fluorescein angiogram. The cumulative distribution of the number of treatments is shown per arm.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":"0"},{"groupId":"OG001","value":"12","spread":"0"},{"groupId":"OG002","value":"10","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Total Area of Lesion at 12 Months","description":"Fluorescein angiography (FA) was used to assess total lesion area. All angiographs were sent to the Central Reading Center (CRC) for analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9178","spread":"5.9455"},{"groupId":"OG001","value":"5.6400","spread":"3.7154"},{"groupId":"OG002","value":"6.3011","spread":"5.4794"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8959","spread":"7.6848"},{"groupId":"OG001","value":"5.8149","spread":"4.6465"},{"groupId":"OG002","value":"8.6245","spread":"7.1242"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0219","spread":"7.7026"},{"groupId":"OG001","value":"0.1749","spread":"4.2357"},{"groupId":"OG002","value":"2.3234","spread":"5.9370"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":32},"commonTop":["CATARACT (Study eye)","EYE HEMORRHAGE (Study eye)","AMD PROGRESSION (Fellow eye)","AMD PROGRESSION (Study eye)","HYPERTENSION"]}}}